Annual CFO
-$520.73 M
+$6.99 M+1.33%
December 31, 2024
Summary
- As of March 12, 2025, BBIO annual cash flow from operations is -$520.73 million, with the most recent change of +$6.99 million (+1.33%) on December 31, 2024.
- During the last 3 years, BBIO annual CFO has fallen by -$22.79 million (-4.58%).
- BBIO annual CFO is now -1186.12% below its all-time high of -$40.49 million, reached on December 31, 2017.
Performance
BBIO Cash From Operations Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly CFO
-$195.33 M
-$14.76 M-8.17%
December 31, 2024
Summary
- As of March 12, 2025, BBIO quarterly cash flow from operations is -$195.33 million, with the most recent change of -$14.76 million (-8.17%) on December 31, 2024.
- Over the past year, BBIO quarterly CFO has dropped by -$14.76 million (-8.17%).
- BBIO quarterly CFO is now -361.47% below its all-time high of $74.70 million, reached on June 30, 2024.
Performance
BBIO Quarterly CFO Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM CFO
-$520.73 M
-$70.51 M-15.66%
December 31, 2024
Summary
- As of March 12, 2025, BBIO TTM cash flow from operations is -$520.73 million, with the most recent change of -$70.51 million (-15.66%) on December 31, 2024.
- Over the past year, BBIO TTM CFO has dropped by -$70.51 million (-15.66%).
- BBIO TTM CFO is now -2800.82% below its all-time high of -$17.95 million, reached on March 31, 2018.
Performance
BBIO TTM CFO Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Cash From Operations Formula
CFO = Net Income + Non Cash Expenses + Changes In Working Capital
BBIO Cash From Operations Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +1.3% | -8.2% | -15.7% |
| 3 y3 years | -4.6% | -8.2% | -15.7% |
| 5 y5 years | -105.3% | -8.2% | -15.7% |
BBIO Cash From Operations Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | -24.1% | +1.3% | -361.5% | +11.0% | -29.1% | +13.6% |
| 5 y | 5-year | -105.3% | +1.3% | -361.5% | +11.0% | -105.3% | +13.6% |
| alltime | all time | -1186.1% | +1.3% | -361.5% | +11.0% | -2800.8% | +13.6% |
BridgeBio Pharma Cash From Operations History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Dec 2024 | -$520.73 M(-1.3%) | -$195.33 M(+8.2%) | -$520.73 M(+15.7%) |
| Sep 2024 | - | -$180.57 M(-341.7%) | -$450.22 M(+8.5%) |
| Jun 2024 | - | $74.70 M(-134.0%) | -$414.88 M(-31.2%) |
| Mar 2024 | - | -$219.54 M(+75.9%) | -$602.93 M(+14.3%) |
| Dec 2023 | -$527.72 M(+25.8%) | -$124.82 M(-14.1%) | -$527.72 M(+6.4%) |
| Sep 2023 | - | -$145.23 M(+28.1%) | -$496.14 M(+2.1%) |
| Jun 2023 | - | -$113.35 M(-21.5%) | -$486.08 M(+20.6%) |
| Mar 2023 | - | -$144.32 M(+54.8%) | -$403.18 M(-3.9%) |
| Dec 2022 | -$419.49 M(-15.8%) | -$93.24 M(-31.0%) | -$419.49 M(-8.8%) |
| Sep 2022 | - | -$135.16 M(+343.8%) | -$460.15 M(+3.0%) |
| Jun 2022 | - | -$30.45 M(-81.0%) | -$446.54 M(-12.1%) |
| Mar 2022 | - | -$160.63 M(+20.0%) | -$507.80 M(+2.0%) |
| Dec 2021 | -$497.93 M | -$133.90 M(+10.1%) | -$497.93 M(+8.2%) |
| Sep 2021 | - | -$121.56 M(+32.5%) | -$460.30 M(-2.2%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Jun 2021 | - | -$91.71 M(-39.2%) | -$470.42 M(+0.8%) |
| Mar 2021 | - | -$150.76 M(+56.6%) | -$466.56 M(+16.7%) |
| Dec 2020 | -$399.71 M(+57.6%) | -$96.26 M(-26.9%) | -$399.71 M(+5.3%) |
| Sep 2020 | - | -$131.68 M(+49.9%) | -$379.66 M(+27.4%) |
| Jun 2020 | - | -$87.85 M(+4.7%) | -$297.97 M(+7.0%) |
| Mar 2020 | - | -$83.92 M(+10.1%) | -$278.37 M(+9.8%) |
| Dec 2019 | -$253.59 M(+85.6%) | -$76.20 M(+52.4%) | -$253.59 M(+13.3%) |
| Sep 2019 | - | -$50.00 M(-26.7%) | -$223.80 M(+5.5%) |
| Jun 2019 | - | -$68.25 M(+15.4%) | -$212.12 M(+19.3%) |
| Mar 2019 | - | -$59.14 M(+27.4%) | -$177.83 M(+30.1%) |
| Dec 2018 | -$136.64 M(+237.5%) | -$46.41 M(+21.1%) | -$136.64 M(+51.4%) |
| Sep 2018 | - | -$38.32 M(+12.9%) | -$90.23 M(+73.8%) |
| Jun 2018 | - | -$33.96 M(+89.2%) | -$51.91 M(+189.2%) |
| Mar 2018 | - | -$17.95 M | -$17.95 M |
| Dec 2017 | -$40.49 M | - | - |
FAQ
- What is BridgeBio Pharma annual cash flow from operations?
- What is the all time high annual CFO for BridgeBio Pharma?
- What is BridgeBio Pharma annual CFO year-on-year change?
- What is BridgeBio Pharma quarterly cash flow from operations?
- What is the all time high quarterly CFO for BridgeBio Pharma?
- What is BridgeBio Pharma quarterly CFO year-on-year change?
- What is BridgeBio Pharma TTM cash flow from operations?
- What is the all time high TTM CFO for BridgeBio Pharma?
- What is BridgeBio Pharma TTM CFO year-on-year change?
What is BridgeBio Pharma annual cash flow from operations?
The current annual CFO of BBIO is -$520.73 M
What is the all time high annual CFO for BridgeBio Pharma?
BridgeBio Pharma all-time high annual cash flow from operations is -$40.49 M
What is BridgeBio Pharma annual CFO year-on-year change?
Over the past year, BBIO annual cash flow from operations has changed by +$6.99 M (+1.33%)
What is BridgeBio Pharma quarterly cash flow from operations?
The current quarterly CFO of BBIO is -$195.33 M
What is the all time high quarterly CFO for BridgeBio Pharma?
BridgeBio Pharma all-time high quarterly cash flow from operations is $74.70 M
What is BridgeBio Pharma quarterly CFO year-on-year change?
Over the past year, BBIO quarterly cash flow from operations has changed by -$14.76 M (-8.17%)
What is BridgeBio Pharma TTM cash flow from operations?
The current TTM CFO of BBIO is -$520.73 M
What is the all time high TTM CFO for BridgeBio Pharma?
BridgeBio Pharma all-time high TTM cash flow from operations is -$17.95 M
What is BridgeBio Pharma TTM CFO year-on-year change?
Over the past year, BBIO TTM cash flow from operations has changed by -$70.51 M (-15.66%)